Losartan Potassium Tablet, Film Coated
Product Images NDC 72789-029

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72789-029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789029 Label (72789029)

Label for Losartan Potassium USP 25 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc. The label specifies a package of 90 tablets, with NDC 72789-029-90. It includes reorder information, lot number G20D60, and expiration date 04/2022. The label features warnings and dosing instructions placeholders, along with manufacturer details from Oklahoma City, OK.*

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over 60 study months between Losartan Potassium and Atenolol. The graph shows time in months on the horizontal axis and percentage of patients on the vertical axis, with Losartan Potassium represented by a solid line and Atenolol by a dotted line. An adjusted risk reduction of 13% is noted with Losartan Potassium, p=0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over 66 study months between Atenolol and Losartan Potassium. Atenolol is represented by a dotted line, showing a higher increase, while Losartan Potassium is a solid line with a lower slope, indicating fewer stroke cases over time.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot figure titled 'Primary Endpoint Events within Demographic Subgroups.' It compares primary composite event rates (%) and stroke event rates (%) between Losartan Potassium and Atenolol across various subgroups. Subgroups include overall results, age, gender, race, ISH, diabetes, and history of cardiovascular disease. Hazard ratios with 95% confidence intervals are displayed graphically with symbols proportional to sample size, indicating comparative risk favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with events over 48 months between Losartan potassium and a placebo. The graph shows risk reduction of 16.1% with a p-value of 0.022, illustrating treatment effect over time.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium, showing its molecular framework including a chlorobenzimidazole and tetrazole moieties, and a potassium ion associated with the tetrazole ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.